Takeaway

• Dapagliflozin failed to significantly reduce the risk for organ failure or mortality, or improve recovery in noncritical patients hospitalized with COVID-19.

Why this matters

• Patients hospitalized with COVID-19 and having cardiometabolic comorbidities are at high risk for serious complications, including multiorgan failure and death.
• There is an unmet need...